Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2006

View Archived Issues

New data on malaria vaccines reported at tropical medicine meeting

Intravenous artesunate investigated in malaria

Pharmacological profile of AstraZeneca's novel P2X7 receptor agonist reported

Novel camptothecin prodrug analogue developed at Chugai

Mochida's novel PARP-1 inhibitor could be a candidate for the treatment of ischemic disorders

Oral bioavailability results support advancement of CK-1827452 into phase II

IND granted for Erwinase

Semafore receives grant to support phase I study of SF-1126

German approval for Eligard six-month formulation

Merck & Co. announces trademark Janumet

Peptech acquires cancer-related antibodies from Scancell

Cell Therapeutics updates pipeline progress

Gene therapy for alpha1-antitrypsin deficiency safe in humans

GCAN-101 preclinical, clinical results show anticancer activity

Rituximab studied in autoimmune diseases

Preclinical data support enhancement of TGF-beta signaling as a treatment for Alzheimer's disease

Novel mGluR1 antagonist developed at Astellas

Recent Kyowa Hakko patent imparts novel p38 MAPK inhibitors

Clera prepares and tests novel dopamine D2 receptor ligands

Spectrum reviews Q3 developments

Nexavar phase III study in melanoma fails to meet primary PFS endpoint

MPI studies with regadenoson comparable to MPI studies with Adenoscan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.